Literature DB >> 281546

Demonstration of antibodies in patients' sera, directed against nonspecific cross-reacting antigen.

S von Kleist, M King, K Havemann.   

Abstract

Nonspecific cross-reacting antigen (NCA), which strongly cross-reacts with carcinoembryonic antigen, was demonstrated to be an autoantigen. Antibodies directed against NCA were shown in different groups of patients, but high titers (greater than 1/64) were found only in cancer patients. A correlation between tumor mass, antigen load, and antibody titer apparently existed. Sera obtained from patients preoperatively and postoperatively differed significantly (P greater than 0.01) in the sense that titers were high only in sera sampled after the patients were treated. Nevertheless, the formation of these antibodies cannot be considered a cancer-specific phenomenon because of their existence also in patients with nonmalignant diseases.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 281546

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  [Demonstration of circulating CEA or CEA-like antigens and immunoglobulin G containing immune complexes in colorectal carcinoma].

Authors:  R Pompecki
Journal:  Klin Wochenschr       Date:  1984-04-02

2.  [Relapse prognosis for patients with adenocarcinoma of the gastrointestinal tract on the basis of carcinoembryonic antigen (CEA) and its circulating immune complexes (author's transl)].

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Klin Wochenschr       Date:  1980-02-01

3.  The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies.

Authors:  M M Konstadoulakis; K N Syrigos; C Albanopoulos; G Mayers; B Golematis
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

4.  Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract?

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.